<DOC>
	<DOCNO>NCT01978028</DOCNO>
	<brief_summary>The primary efficacy objective study evaluate effect ferric carboxymaltose mitochondrial gene activation pattern 12 week treatment .</brief_summary>
	<brief_title>Differential Gene Expression Patients With Heart Failure Iron Deficiency - Effects Ferric Carboxymaltose</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Patients chronic heart failure New York Heart Association Class II III , leave ventricular ejection fraction ≤ 40 % patient NYHA class II ≤ 45 % patient NYHA class III , hemoglobin level screen visit 9.513.5 g/dl , iron deficiency , define serum ferritin level &lt; 100µg/l 100 299 µg/l , transfer saturation &lt; 20 % . Age ≥18 year Obtained informed consent Stable pharmacological therapy last 4 week ( exception diuretic ) Hemochromatosis , iron overload , define TSAT &gt; 45 % Known hypersensitivity Ferinject® . Known active infection , CRP &gt; 20 mg/L , clinically significant bleeding , active malignancy . Chronic liver disease and/or screen alanine transaminase ( ALT ) aspartate transaminase ( AST ) three time upper limit normal range . Immunosuppressive therapy renal dialysis ( current plan within next 6 month ) . History erythropoietin , i. v. oral iron therapy , blood transfusion previous 12 week and/or therapy plan within next 6 month . Unstable angina pectoris judge investigator , clinically significant uncorrected valvular disease leave ventricular outflow obstruction , obstructive cardiomyopathy , poorly control fast atrial fibrillation flutter , poorly control symptomatic brady tachyarrhythmias . Acute myocardial infarction acute coronary syndrome , transient ischemic attack stroke within last 3 month . Coronaryartery bypass graft , percutaneous intervention ( e.g . cardiac , cerebrovascular , aortic ; diagnostic catheter allow ) major surgery , include thoracic cardiac surgery , within last 3 month . Participation CHF train program . Known HIV/AIDS . Inability fully comprehend and/or perform study procedure investigator 's opinion . Vitamin B12 and/or serum folate deficiency accord laboratory ( rescreening possible substitution therapy ) . Pregnancy lactation . Participation another clinical trial within previous 30 day and/or anticipated participation another trial study . Anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>heart failure</keyword>
</DOC>